U.S. FDA approves Taiwan-developed drug to treat rare blood disease

Taiwanese pharmaceutical company PharmaEssentia Corp. has received approval from the U.S. Food and Drug Administration for its new drug that treats adults with a rare blood disease, the company said Monday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)